Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial / William J. Burke en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 423-427 Título : Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial Tipo de documento: texto impreso Autores: William J. Burke, Autor ; Shelton E. Hendricks, Autor ; Delores McArthur Miller, Autor Fecha de publicación: 2023 Artículo en la página: pp. 423-427 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos de segunda generación, Trastorno depresivo, Fluoxetina. Resumen: Fluoxetine (FLX) has a unique pharmacokinetic profile. Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies. This study examined the tolerability of a weekly dose and its equivalence to daily dosing of FLX for the continuation phase of treatment for major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=31178 [artículo] Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial [texto impreso] / William J. Burke, Autor ; Shelton E. Hendricks, Autor ; Delores McArthur Miller, Autor . - 2023 . - pp. 423-427. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 423-427 Palabras clave: Antidepresivos de segunda generación, Trastorno depresivo, Fluoxetina. Resumen: Fluoxetine (FLX) has a unique pharmacokinetic profile. Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies. This study examined the tolerability of a weekly dose and its equivalence to daily dosing of FLX for the continuation phase of treatment for major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=31178

---

1 (1 - 1 / 1)